1. A new standard in graft-versus-host disease prophylaxis? An introduction to Blood and Marrow Transplant Clinical Trials Network 1703;DeFilipp;Biol Blood Marrow Transplant,2020
2. US Food and Drug Administration. FDA expands ibrutinib indications to chronic GVHD. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-ibrutinib-indications-chronic-gvhd. Accessed March 15, 2022.
3. US Food and Drug Administration. FDA approves ruxolitinib for chronic graft-versus-host disease. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-chronic-graft-versus-host-disease. Accessed March 15, 2022.
4. US Food and Drug Administration. FDA approves belumosudil for chronic graft-versus-host disease. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belumosudil-chronic-graft-versus-host-disease. Accessed March 15, 2022.
5. Chronic graft-versus-host disease;Lee;Biol Blood Marrow Transplant,2003